

**COMMONWEALTH OF MASSACHUSETTS
Board of Registration in Pharmacy**

**NOTICE OF THE REGULARLY SCHEDULED MEETING OF THE
BOARD OF REGISTRATION IN PHARMACY**

April 5, 2016
239 Causeway Street ~ Room 417 A&B
Boston, Massachusetts 02114

Agenda

Time	#	Item	Exhibits	Contact
8:30	I	CALL TO ORDER		E. Taglieri
8:35	II	APPROVAL OF AGENDA Introduction of Pharmacy Intern(s)		
8:40	III	APPROVAL OF BOARD MINUTES <ul style="list-style-type: none"> • Draft of March 1, 2016 Regular Session Minutes 		
8:45	IV	PRESCRIPTION MONITORING PROGRAM UPDATE		E. Sheehan
9:15	V	APPLICATIONS <ul style="list-style-type: none"> • IVG Veterinary Compounding Pharmacy – Transfer of Ownership • Coram/CVS Specialty Infusion- Renovation/Expansion. 		
10:00	VI	REPORTS <ul style="list-style-type: none"> • Applications approved pursuant to Licensure Policy 13-01 • Monthly Report from Probation 	Reports	R. Harris K. Fishman
10:05	VII	FLEX SESSION <ul style="list-style-type: none"> • NABP Annual meeting 		D. Sencabaugh
10:20	VIII	POLICIES <ul style="list-style-type: none"> • Outsourcing Facility Registration Transition Plan • Outsourcing Facility Staff Action Policy • Division Policy 16-01 Routine Responses 		V. Berg
10:45	IX	REGULATIONS <ul style="list-style-type: none"> • Proposed new regulations 247 CMR 19:00 – Hazardous Drugs 		W. Frisch M. Chan

11:30	X	<p>FILE REVIEW</p> <ol style="list-style-type: none"> 1. SA-INV-7899, CVS #2500, DS3606 2. PHA-2015-0126, CVS #1886, DS3334 3. SA-INV-7520, Coram CVS Specialty Infusion, DS3601 4. PHA-2016-0008, CVS #610, DS24018 5. SA-INV-8816, CVS #2200, DS2767 6. PHA-2015-0027, CVS #220, DS17722 7. PHA-2015-0095. Katie Ruth Blais, PH233923 8. SA-INV-7900, Rite Aid #10172, DS2405 9. SA-INV-7213, PharmaHealth Pharmacy, DS3056 10. SA-INV-8123, Winchendon Family Pharmacy, DS89843 11. SA-INV-7376, Preferred Pharmacy, DS3542 12. SA-INV-8938, Janet Troche, PT17388 13. PHA-2015-0073, Sullivan’s Pharmacy, DS3335 14. SA-INV-9058, Pepperell Family, DS3541 15. SA-INV-8237, Ashburnham Family Pharmacy, DS3314 		
12:30		LUNCH BREAK		
1:30	XI	<p>EXECUTIVE SESSION</p> <p>The Board will meet in Executive Session as authorized pursuant to M.G.L. c. 30A, § 21(a)(1) for the purpose of discussing the reputation, character, physical condition or mental health, rather than professional competence, of an individual, or to discuss the discipline or dismissal of, or complaints or charges brought against, a public officer, employee, staff member or individual.</p> <p>Specifically, the Board will discuss and evaluate the Good Moral Character as required for registration for pending applicants.</p>	CLOSED SESSION	
2:30	XII	ADJUDICATORY SESSION (M.G.L. c. 30A, § 18)	CLOSED SESSION	
3:15	XIII	M.G.L. c. 112, § 65C SESSION	CLOSED SESSION	
5:00	XIV	ADJOURNMENT		

**COMMONWEALTH OF MASSACHUSETTS
BOARD OF REGISTRATION IN PHARMACY**

**MINUTES OF THE REGULARLY SCHEDULED MEETING
239 Causeway Street, Fourth Floor Room 417A
Boston Massachusetts, 02114**

April 5, 2016

Board Members Present

Edmund Taglieri Jr., R.Ph, MSM, NHA
President
FACA Karen Conley, RN, DNP
President –elect
Garrett Cavanaugh, RPh
Michael Godek, R.Ph, Secretary
Phillippe Bouvier, R.Ph.
Catherine Basile, Pharm D, R.Ph.
Susan Cornacchio, JD
William Cox CPhT (arrived at 8:40)
Andrew Stein, Pharm D, R.Ph.
Richard Tinsley, MBA, M.Ed.,

Board Members Not Present

Patrick Gannon, RPh, MS
Richard Tinsley, MBA, M.Ed. Timothy Fensky, R.Ph,

Ali Raja, MD, M.B.A., M.P.H.

Board Staff Present

David Sencabaugh, RPh, Executive Director
William Frisch, Director of Pharmacy Compliance
Kelly Barnes, Director of Pharmacy Quality Assurance
Heather Engman, JD, MPH Board Counsel
Sam Leadholm, JD, Board Counsel
Richard Harris, Program Analyst
Monica Vasquez, Compliance Officer
Julienne Tran, PharmD, RPh. Pharmacy Investigator
Christina Mogni, R. Ph., Pharmacy Investigator
Cheryl Lathum, Pharm D., R.Ph., Senior Investigator
Greg Melton, JD, R.Ph., Pharmacy Investigator
Vita Palazzolo Berg, JD, Chief Board Counsel
Karen Fishman, Probation Monitor

TOPIC: I

CALL TO ORDER 8:30 AM

DISCUSSION: A quorum of the Board was present, established by roll call. President E. TAGLIERI chaired the meeting and asked if anyone was recording. Hearing “no”, he explained that the Board of Pharmacy was recording the meeting. D. SENCABAUGH introduced APPE students Brian Ho from Northeastern University and Mei Zou, from MCPHS University.

TOPIC II.

APPROVAL OF AGENDA

DISCUSSION: The open file review on Sullivans Pharmacy, Winchendon Family Pharmacy, and Ashburnham Family Pharmacy will be deferred.

ACTION:

1. Motion by M. GODEK, seconded by, C. BASILE, and voted unanimously to approve the agenda (W. COX had not yet arrived)..

TOPIC III.

APPROVAL OF BOARD MINUTES

1. Draft March 1, 2016, Regular Session Minutes

DISCUSSION: Need to correct minutes by removing M Godek from the “affirmative” section of applications, specifically on the Nimble Pharmacy vote.

ACTION:

2. Motion by M. GODEK, seconded by, P. BOUVIER, and voted unanimously to approve the minutes of the General Session from March 1, 2016, with the noted change (W. COX had not yet arrived).

TOPIC IV:

PMP Program Update

Eric Sheehan, Interim Bureau Director HCSQ, presented an overview of the new PMP program, scheduled to be released this spring. Sheehan was joined by Director of OPMD and Tom Innis of the Ripples Group. Sheehan explained that the new program will have the capability to connect with up to 42 states when it comes to the “go live” date of 5/31/16.

TOPIC V:

APPLICATIONS

TIME: 9:10AM-10:14AM

1. IVG Veterinary Compounding Pharmacy Transfer of Ownership

DISCUSSION: IVG was represented by Veterinarian Dr. Patrick Welch and Attorney Sean Ryan of Donoghue Barrett & Singal. Ethos Veterinary Health LLC is the new owner of IVG. Since ownership of Ethos consists of eighteen out-of-state veterinarians, they are simultaneously seeking the expansion of a waiver to 247 CMR 6.01(3), allowing such ownership. After making the case that there is a compelling reason to grant the waiver, and answering the Board Member’s questions about the owner veterinarians writing prescriptions that will be filled at IVG, the Board members were satisfied.

3. ACTION: Motion by T. FENSKY, seconded by, C. BASILE, and voted unanimously, to approve the application for the transfer of ownership and the waiver.

2. Coram/CVS Specialty Pharmacy Renovation/Expansion

RECUSAL: Susan Cornacchio recused and was not present during discussion or voting on this topic.

DISCUSSION: Coram/CVS was represented by MOR Shamir Patel and Attorney Joe Lavino. The discussion centered around the ratification by the Board of the Board Staff’s approval of “Phase I” (limited compounding performed with an isolator) of a 4-phased plan to renovate and expand the sterile compounding facility, and the request by Coram to expand the Phase I approach to include refills. Director of Quality Assurance, K. Barnes and Director of Compliance, W. Frisch, expressed concerns about such expansion, based on the history of abnormal results at the facility, and other issues of concern. Board Members asked for clarification of what Coram was looking for them to vote on. MOR Patel stated that they wanted permission to compound the first dose, 1st refills, and subsequent refills on low risk CSPs, as well as some limited ability to do the same for medium risk CSPs. There was action on that request.

4. ACTION: Motion by T. FENSKY, seconded by W. COX, to approve the request by Coram, and voted unanimously to OPPOSE said request.

5.

6. ACTION: Motion by T. FENSKY, seconded by C. BASILE, to approve the first fill on low risk and limited medium (what was approved by Staff already) and voted unanimously, to approve the Phase I as initially approved by Board Staff, for a maximum of 90 days.

7.

TOPIC VI.

REPORTS

Applications Approved Pursuant to Licensure Policy 13-01

DISCUSSION: R. HARRIS noted that during the past month there have been thirty-eight (38) change of managers, and four (4) renovation/expansions since the last Board meeting.

ACTION: So noted

Report of activities Probation Monitor

DISCUSSION: K. FISHMAN provided the February 23, 2016 – March 25, 2016, Board of Pharmacy Statistics Report for the Probation monitor, which noted that: there are (59) licensees on probation, thirteen (13) satisfactorily completed probation, two (2) licensee did not cure within 30 days, and four (4) given the opportunity to cure.

ACTION: So noted

TOPIC VII.

Flex Session

1. NABP Annual Meeting

DISCUSSION: D. SENCABAUGH updated the Board on the NABP Annual Meeting being held in San Diego, CA May 14 – 17. T. FENSKY will be attending as the voting delegate, and he is also running for the District I seat on the NABP Executive Committee. Sencabaugh also reminded the Board the two resolutions (resolving that NABP convene a task force to study white bagging and brown bagging and form a position, and that NABP should ask the FDA to make Naloxone OTC) previously approved for the District Meeting last fall, would be brought to vote at the Annual Meeting

TOPIC VIII

Policies

Division Policy 16-01 Routine Responses

Vita Berg

10:05am

DISCUSSION:

Chief Board Counsel Vita Berg presented a request for the Board to approve the Policy (16-01), to facilitate staff responses to routine correspondence and requests for extensions. Board council would prepare the responses.

ACTION: At 10:15 am motion by P. BOUVIER, seconded by W.COX, and voted unanimously to approve policy 16-01 routine responses.

E. TAGLIERI: yes, T. FENSKY; yes, M.GODEK: yes, C. BASILE; yes, G. CAVANAUGH: yes, S. CORNACCHIO: yes, P.BOUVIER: yes, A. STEIN: yes, W.COX

TOPIC VIII

Outsourcing Facility Registration Transition Plan

10:00 am

DISCUSSION: Transition plan for non-resident plan between now-Oct. 1. Outsourcers located outside of MA must hold a non-resident license. Getting the word out for hospitals and outsourcing facilities. Facilities that may have not been inspected by the FDA within the past two years would have until September 30, 2016 to be inspected. V. BERG noted typo.

ACTION: At 10:05 am motion by W. COX, seconded by M.GODEK, and voted unanimously to approve Registration of Non-Resident Outsourcing Facilities in Massachusetts transition plan, with the noted typo fix..

E. TAGLIERI: yes, T. FENSKY; yes, M.GODEK: yes, C. BASILE; yes, G. CAVANAUGH: yes, S. CORNACCHIO: yes, P.BOUVIER: yes, A. STEIN: yes, W.COX

TOPIC VIII

Policies

Outsourcing Facility Staff Action Policy

Vita Berg

10:07am

DISCUSSION:

Staff action policy to authorize Board staff to process and act on applications pertaining to outsourcing facilities as described on 247 CMR 11.00 and 247 CMR 21.00. Applicants must meet criteria. This would allow the staff to issue registrations to outsourcing facilities, even if they had received a “warning letter” from the FDA, as long as they were not prohibited from commercial distribution.

ACTION: At 10:11 am motion by C. BASILE, seconded by T.FENSKY, and voted unanimously to approve Outsourcing Facility Staff Action Policy.

E. TAGLIERI: yes, T. FENSKY; yes, M.GODEK: yes, C. BASILE; yes, G. CAVANAUGH: yes, S. CORNACCHIO: yes, P.BOUVIER: yes, A. STEIN: yes, W.COX

•

TOPIC IX:

REGULATIONS

TIME: 10:26am

247 CMR 19.00 New Section-Hazardous Medications

Presented by Kelly Barnes/William Frisch/Michelle Chan

W. FRISCH indicated sections highlighted in yellow are the more recent changes. Definitions still need to be crafted.

Section 19.01: Ed suggested defining sections 247 CMR 17 and 18 and add <795> and <797>. K. BARNES indicated reader can refer to those sections. 247 CMR is noted in other parts of the regulations.

19.01 (4) W. FRISCH noted USP <797> chapter makes references to chemicals. Should chemicals be included in the Safety Data Sheets requirement?

19.03 (3) S. CORNACCHIO indicated #3 should be communicated and documented. Mark up so it can be enforced.

19.04(2) (a) K BARNES Overview of the risk of handling drugs added to the list.

19.02(3) K. BARNES referenced back to 19.02 (3) Review hazardous drugs annually. Requirement for keeper of the list including the creation and update of the list. Define all changes made.

19.05 W. FRISCH changed should to shall. Chapter leaves it up to the entity on how they want to store HDs. Up to the facility who they will store other medications that are deemed hazardous according to the facility (i.e. tacrolimus). K.BARNES indicated also to consider medications such as clonazepam and risperidone which are considered hazardous but not manipulated.

E. TAGLIERI suggested facility writes a policy and procedure for storage.

19.05 (16) W. FRISCH-Chapter suggested using Closed System Transfer Devices (CSTD) when available for HD meds but there as no clear understanding of it. Can't use CST as a substitute for a C-PEC.

19.05(18) W.FRISCH- There are examples where facilities have BSC's that are not vented externally. As long as facilities have BSCs, they need to be certified properly.

19.05 (20) W. FRISCH- It is not clear in chapter. It is implied you need a separate room for non-sterile, HD and non- HD medications. 247 CMR 18 calls for dedicated room. Can non-HD and HD medications coexist in same

room provided they have separate PECs? As it stands non-sterile, non-HD and HDS meds need to be separated per the experts but need more information.

19.05 (23) Stricter than standard, LAWF and CAI must not be used for the compounding of HDs.

19.05 (26) W. Frisch-Asks for exemptions. Need Board approval if asking for exemption. K. Barnes Policies and procedures for implementation of co-mingling. Need caution “cytotoxic” labeled on CSP. Wording important to trigger the next health professional to use caution.

W. Frisch- Are compounders going to be able to prepare non-HD in same hood?

19.05 (31) T. FENSKY- is room size defined?

K. BARNES- Room size needs to be followed as other regs.

19.07 (8) K. BARNES –Overalls: need to make sure they are available. Phrasing may change. W. FRISCH-If it's not permeable need to use chemo coveralls and verifies that it works. Process flow for booties.

19.08 (9) W. FRISCH- need to expand beyond antineoplastics. K.BARNES- If HD list created should differentiate between levels and handling. T.FENSKY-Example-if risperidone need counting tray vs. Kirby Lester? K. BARNES-can put HD in ADM if no risk of crushing. W.FRISCH- Need to look at crushing tab issues and if there could be cross contamination.

ACTION: None Taken. The section discussion will continue during the next meeting.

TOPIC X:
OPEN FILE REVIEW

I. Open File Review

Case #1

SA-INV-7899 CVS Pharmacy #2500 DS3606 TIME: 11:30 am

RECUSAL: S. CORNACCHIO recused and was not present for the discussion or vote on this matter.

DISCUSSION: C. MOGNI presented and summarized the investigation report that pertained to these matters.

- Large amounts of CII observed ordered and dispensed during 7/2015 inspection.
- Review of PMP revealed no red flags - 1 patient/1 prescriber, fills not early, few large quantities
- DEA contacted – no open investigation

ACTION: Motion by C. BASILE, seconded by W. COX, and voted unanimously by those present, to CLOSE SA-INV-7899 with NO VIOLATION.

Case #2

PHA-2015-0126 CVS Pharmacy #1886 DS3334 TIME: 11:31 am

RECUSAL: S. CORNACCHIO recused and was not present for the discussion or vote on this matter.

DISCUSSION: C. MOGNI presented and summarized the investigation report that pertained to these matters.

- Self-report by 106 form of an unknown loss of 6,661 APAP/codeine #3 on 06/30/2015
- Reconciliation of 2013 biennial inventory to 2015 biennial inventory showed a loss on paper
- CVS Loss Prevention with MOR John-Hope conducted an extensive investigation and loss could not be accounted for as diversion
- Daily cycle counts performed by overnight pharmacist 06/24/2015 to 08/09/2015 with no discrepancies
- RLPM Leonard conducted a reconciliation 05/01/2015 to 08/03/2015 which revealed an overage, no loss

ACTION: Motion by M. GODEK, seconded by T. FENSKY, and voted unanimously by those present, to hold INVESTIGATIVE CONFERENCE with CVS corporate leadership (loss prevention and MOR) for strategies reevaluation.

Case #3

SA-INV-7520 Coram CVS Specialty Infusion DS3601 TIME: 11:37 am

RECUSAL: S. CORNACCHIO recused and was not present for the discussion or vote on this matter.

DISCUSSION: J. TRAN presented and summarized the investigation report that pertained to these matters.

- Coram had 1 cfu/m³ of Rhodotorula species (yeast) isolated from one air sample taken on May 18, 2015 in the ISO 8 prep room.
- Coram initially suspended compounding and remediated, then utilized reduced BUD.
- Follow up testing from June 1 isolated Cladosporium species (fungus) from the ISO 8 room.
- Coram remediated again to include cleaning, an evaluation of the air handling system and staff observation.
- Follow up testing from June 15 testing indicated no USP <797> actionable results.

ACTION: Motion by T. FENSKY, seconded by C. BASILE, and voted unanimously by those present, to CLOSE SA-INV-7520 with NO VIOLATION.

Case #4

PHA-2016-0008 CVS Pharmacy #610 DS24018 TIME: 11:39 am

RECUSAL: S. CORNACCHIO recused and was not present for the discussion or vote on this matter.

DISCUSSION: J. TRAN presented and summarized the investigation report that pertained to these matters.

- Pharmacy had inspectional deficiencies on October 28, 2015 due to lack of consistent recording of refrigerator/freezer temperature logs and unsanitary pharmacy conditions.
- MOR submitted 3 months of temperature logs. Analysis of the temperature logs revealed 102 occasions of non-compliance. Deficiencies corrected in the Plan of Correction (POC).
- Investigator Horn conducted a retail pharmacy inspection (ISP-4372) on January 27, 2016. No deficiencies were noted.

ACTION: Motion by A. STEIN, seconded by W. COX, and voted unanimously by those present, to DISMISS PHA-2016-0008, further discipline not warranted, remediation complete.

Case #5

SA-INV-8816 CVS Pharmacy #2200 DS2767 TIME: 11:44 am

RECUSAL: S. CORNACCHIO recused and was not present for the discussion or vote on this matter.

DISCUSSION: J. TRAN presented and summarized the investigation report that pertained to these matters.

- Multiple deficiencies noted by Investigators during a previous 1/21/15 (ISP-2812) inspection included: No POA on file, overstocked meds in fridge and on the door, compounding equipment and area were dirty, inconsistent BUD and compounding records.
- Multiple deficiencies noted by Investigators during a September 30, 2015 (ISP-3793) inspection.
- Deficiencies with repeated deficiencies of unsanitary compounding equipment; lack of MOR name display, perpetual inventory logs that do not reflect expired controlled substances and freezer noted with excessive frost build up.
- MOR Meschwitz stated that the deficiencies were the result of being a relatively new MOR; however the name display was installed on February 2, 2016. The compounding station was cleaned and is now cleaned regularly. Additionally, the Fill Master was replaced with a new unit on February 2, 2016. Expired controlled substances are now recorded on the perpetual inventory until their return to the reverse distributor. Also, the freezer was defrosted and completed on a regular basis.
- Investigator Horn conducted a retail inspection (ISP-4373) on January 25, 2016. No deficiencies were noted.

ACTION: Motion by C. BASILE, seconded by G. CAVANAUGH, and voted unanimously by those present, to CLOSE SA-INV-8816 with no further discipline warranted, remediation complete.

Case # 6.

CVS # 220; DS17722; PHA-2015-0027:

DISCUSSION: Cheryl Lathum presented and summarized the investigation report.

ACTION: Motion by Tim Fensky, seconded by Garrett Cavanaugh, and voted unanimously to refer the matter to the office of prosecution and to authorize resolution of the matter with a consent agreement for reprimand.

RECUSAL: Susan Cornacchio

Case # 7.

Katie Ruth Blais; PH233923; PHA-2015-0095

DISCUSSION: Cheryl Latham presented and summarized the investigation report.

ACTION: Motion by Cathy Basile, seconded by Michael Godek, and voted unanimously to dismiss the complaint, discipline not warranted.

RECUSAL: Susan Cornacchio

Case #8.

Rite Aid # 10172; DS2405; SA-INV-7900

DISCUSSION: Christina Mogni presented and summarized the investigation report.

ACTION: Motion by Michael Godek, seconded by Philippe Bouvier, and voted unanimously to close the staff assignment, no violation.

RECUSAL: Garrett Cavanaugh and William Cox

Case #9.

PharmaHealth Pharmacy; DS3056; SA-INV-7213

DISCUSSION: Bill Frisch presented and summarized the investigation report.

ACTION: Motion by Tim Fensky, seconded by Cathy Basile, and voted unanimously to close the staff assignment due to insufficient evidence.

Case #10.

Wichendon Family Pharmacy; DS89843; SA-INV-8123

Matter deferred to future meeting

Case #11

SA-INV-7376 Preferred Pharmacy, DS3542 TIME: 11:58 am

RECUSAL: None

DISCUSSION: M. VASQUEZ presented and summarized the investigation report that pertained to these matters.

- Report of mold from the gowning room on March 25, 2015
- MOR ceased compounding on April 17, 2015, out sourced to another pharmacy, cleaned, removed extra items from the ante room, reduced traffic in the ante room, conducted a RCA.

Follow-up EM was conducted by an outside vendor and yielded no USP <797> action levels.

ACTION: Motion by M. GODEK, seconded by W. COX, and voted unanimously by those present to close assignment, discipline not warranted, remediation completed.

Case #12

SA-INV-8938

Janet Troche, PT17388

TIME: 11:59 am

RECUSAL: None

DISCUSSION: M. VASQUEZ presented and summarized the investigation report that pertained to these matters.

- Board received anonymous call that Technician Troche may have falsified her application.
- It was alleged the technician never graduated high school.
- Technician has worked in Stop and Shop in Lynn for 5 years.
- Was not able to provide evidence of graduation since her high school in Puerto Rico burned down and all documentation was destroyed
- Pharmacy Manager provided a letter supporting technician's work ethic.

ACTION: Motion by M. GODEK, seconded by W. COX, and voted unanimously by those present to waive her requirement to provide documentation, and close assignment, no violation.

Case #13

SA-INV-9058

Pepperell Family Pharmacy, DS3541

TIME: 12:01pm

RECUSAL: None

DISCUSSION: G. MELTON presented and summarized the investigation report that pertained to these matters.

- Pharmacist Technician Trainee was noted on application for registration as a pharmacy technician to have been in excess of the 1000 hour limitation on employment.
- The trainee noted working 1600 hours on the application. In addition, the application was certified by the MOR
- For POC, MOR rushed to complete the application and miscalculated number of hours training. The corrected hours are 950.
- MOR noted the trainee has been working as a cashier only since submitted the application for registration as a technician.
- MOR now dedicates additional time and attention to monitoring trainee hours and while preparing applications for registration as a pharmacy technician
- Application is still ACTION: Motion by T. FENSKY, seconded by C. BASILE, and voted unanimously by those present to close assignment, no violation.

TOPIC XI.

EXECUTIVE SESSION:

DISCUSSION: None

ACTION: at 1:34PM motion by R. TINSLEY, seconded by C. BASILE, and voted unanimously by roll call to enter into Executive Session: E. TAGLIERI; yes, T. FENSKY; yes, M. GODEK; yes, P. BOUVIER; yes, C. BASILE; yes, S. CORNACCHIO; yes, W. COX; yes, A. RAJA; yes, A. STEIN; yes, R. TINSLEY; yes.

TOPIC XII.

ADJUDICATORY SESSION: at 11:35AM, motion by T. FENSKY, seconded by R. TINSLEY, and voted unanimously to enter Adjudicatory Session:

TOPIC XIII.

M.G.L. c. 65C Session

DISCUSSION: None

ACTION: At 2.34PM motion by R. TINSLEY, seconded by C. BASILE and voted unanimously to enter into M.G.L. c. 65C Session.

TOPIC XIV.

ADJOURNMENT OF MEETING

DISCUSSION: NONE

ACTION: At 4:47PM motion by M. GODEK, seconded by C. BASILE, and voted unanimously to adjourn the meeting.

LIST OF EXHIBITS USED DURING THE OPEN SESSION OF THE MEETING

8. Draft Agenda for the April 5, 2016, regularly scheduled meeting of the Board of Registration in Pharmacy.
9. Draft March 1, 2016 Open Session Minutes.
10. Application to Transfer Ownership and waive 247 CMR 6.01(3), IVG Veterinary Pharmacy.
11. Application to Renovate and Expand, Coram/ CVS DS3601, Norwood, MA.
12. Report of Applications approved pursuant to licensure policy 13-01
13. Report from Probation Monitor 2/23/2016 – 3/25/2016
14. 10. Draft proposed Policy amendments to 247 CMR 16-01, Outsourcing Facilities
15. 11. Draft new proposed Policy 16-02 Guidance for Filing DEA 106 Forms
16. 12. Draft Division Policy 16-01 Routine Responses
17. 13. Draft proposed new regulation 247 CMR 19.00: Hazardous Drugs
18. 14. Investigation report in the matter of CVS 2500 DS3606, SA-INV-7899
19. 15. Investigation report in the matter of CVS 1886, DS3334, PHA-2015-0126
20. 16. Investigation report in the matter of Coram/ CVS DS3601, SA-INV-7520
21. 17. Investigation report in the matter of CVS #220, DS17722, PHA-2015-0027
22. 18. Investigation report in the matter of Katie Ruth Blais, PH233923, PHA-2015-0095.
23. 19. Investigation report in the matter of Rite Aid #10172, DS2405, SA-INV-7900
24. 20. Investigation report in the matter of PharmaHealth Pharmacy, DS3056, SA-INV-7213
25. 21. Investigation report in the matter of Preferred Pharmacy, DS3542, SA-INV-7376
26. 22. Investigation report in the matter of Janet Troche, PT17388, SA-INV-8938
27. 23. Investigation report in the matter of Pepperell Family Pharmacy, DS3541, SA-INV-9058
- 28.
29. Respectfully submitted by:
M. GODEK, R.Ph.
